Skip to Content
Merck
  • Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Cancer immunology, immunotherapy : CII (2014-08-20)
Lindsey Chudley, Katy J McCann, Adam Coleman, Angelica M Cazaly, Nicole Bidmon, Cedrik M Britten, Sjoerd H van der Burg, Cecile Gouttefangeas, Camilla Jandus, Karoline Laske, Dominik Maurer, Pedro Romero, Helene Schröder, Linda F M Stynenbosch, Steffen Walter, Marij J P Welters, Christian H Ottensmeier
ABSTRACT

Ex vivo ELISPOT and multimer staining are well-established tests for the assessment of antigen-specific T cells. Many laboratories are now using a period of in vitro stimulation (IVS) to enhance detection. Here, we report the findings of a multi-centre panel organised by the Association for Cancer Immunotherapy Immunoguiding Program to investigate the impact of IVS protocols on the detection of antigen-specific T cells of varying ex vivo frequency. Five centres performed ELISPOT and multimer staining on centrally prepared PBMCs from 3 donors, both ex vivo and following IVS. A harmonised IVS protocol was designed based on the best-performing protocol(s), which was then evaluated in a second phase on 2 donors by 6 centres. All centres were able to reliably detect antigen-specific T cells of high/intermediate frequency both ex vivo (Phase I) and post-IVS (Phase I and II). The highest frequencies of antigen-specific T cells ex vivo were mirrored in the frequencies following IVS and in the detection rates. However, antigen-specific T cells of a low/undetectable frequency ex vivo were not reproducibly detected post-IVS. Harmonisation of the IVS protocol reduced the inter-laboratory variation observed for ELISPOT and multimer analyses by approximately 20 %. We further demonstrate that results from ELISPOT and multimer staining correlated after (P < 0.0001 and R (2) = 0.5113), but not before IVS. In summary, IVS was shown to be a reproducible method that benefitted from method harmonisation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in E. coli, ~10000 U/mL
Sigma-Aldrich
Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, carrier free
Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in HEK 293 cells, suitable for cell culture, endotoxin tested
Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in Pichia pastoris, suitable for cell culture
Sigma-Aldrich
IL-2 from rat, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
Interleukin-2, human, Animal-component free, recombinant, expressed in E. coli, suitable for cell culture